HomeCompareBCEL vs KMB

BCEL vs KMB: Dividend Comparison 2026

BCEL yields 2222.22% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BCEL wins by $26607504688.21M in total portfolio value
10 years
BCEL
BCEL
● Live price
2222.22%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26607504688.26M
Annual income
$24,443,703,761,807,280.00
Full BCEL calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — BCEL vs KMB

📍 BCEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBCELKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BCEL + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BCEL pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BCEL
Annual income on $10K today (after 15% tax)
$188,888.89/yr
After 10yr DRIP, annual income (after tax)
$20,777,148,197,536,188.00/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, BCEL beats the other by $20,777,148,197,531,748.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BCEL + KMB for your $10,000?

BCEL: 50%KMB: 50%
100% KMB50/50100% BCEL
Portfolio after 10yr
$13303752344.15M
Annual income
$12,221,851,880,906,252.00/yr
Blended yield
91.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

BCEL
Analyst Ratings
4
Buy
4
Hold
Consensus: Buy
Price Target
$4.00
+4344.4% upside vs current
Range: $4.00 — $4.00
Altman Z
-37.6
Piotroski
3/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BCEL buys
0
KMB buys
0
No recent congressional trades found for BCEL or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBCELKMB
Forward yield2222.22%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$26607504688.26M$45.9K
Annual income after 10y$24,443,703,761,807,280.00$5,222.34
Total dividends collected$26455115546.17M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$4.00$123.00

Year-by-year: BCEL vs KMB ($10,000, DRIP)

YearBCEL PortfolioBCEL Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$232,922$222,222.22$11,314$614.45+$221.6KBCEL
2$5,086,656$4,837,429.33$12,867$760.19+$5.07MBCEL
3$104,173,443$98,730,720.93$14,713$945.27+$104.16MBCEL
4$2,001,166,924$1,889,701,340.37$16,924$1,181.90+$2001.15MBCEL
5$36,067,485,611$33,926,237,001.88$19,596$1,486.64+$36067.47MBCEL
6$610,050,404,477$571,458,194,873.63$22,850$1,882.16+$610050.38MBCEL
7$9,686,139,336,337$9,033,385,403,546.24$26,849$2,399.80+$9686139.31MBCEL
8$144,409,519,569,037$134,045,350,479,156.38$31,812$3,083.36+$144409519.54MBCEL
9$2,022,243,856,495,371$1,867,725,670,556,501.50$38,033$3,994.72+$2022243856.46MBCEL
10$26,607,504,688,257,330$24,443,703,761,807,280.00$45,918$5,222.34+$26607504688.21MBCEL

BCEL vs KMB: Complete Analysis 2026

BCELStock

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

Full BCEL Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this BCEL vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BCEL vs SCHDBCEL vs JEPIBCEL vs OBCEL vs KOBCEL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.